ArticleIn vivo (Athens, Greece)
Nintedanib Treatment of Patients With Interstitial Lung Diseases: A Retrospective Study of Daily Clinical Practice.
Article in In vivo (Athens, Greece). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND/
aimNintedanib, an antifibrotic drug, is expected to slow the progression of interstitial lung diseases (ILDs). This study aimed to evaluate the usefulness of nintedanib for patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) who would otherwise be excluded due to being unable to undergo invasive tests. PATIENTS AND
methodsWe retrospectively reviewed the medical records of all IPF and PPF patients who received nintedanib at our hospitals. This study included 187 patients whose severity could be assessed using the Japanese Respiratory Society classification, which allows for non-invasive severity evaluation, rather than the Gender-Age-Physiology score. Patients were classified into three groups based on their nintedanib administration status: a continuation group, a dose reduction group, and a discontinuation group.
resultsThere were no significant differences in patient characteristics among the three groups. The duration of nintedanib administration in the discontinuation group was shorter than in the continuation and dose reduction groups. There was a significant difference in survival time from the start of nintedanib administration, with a shorter survival time in the discontinuation group. In addition, the incidence of acute exacerbations was lower in the continuation and the dose reduction groups than in the discontinuation group. Developing an acute exacerbation and discontinuation of nintedanib administration were identified as poor prognostic factors.
conclusionEven in patients with ILD who would be excluded due to selection bias, continuing nintedanib might show positive effects on survival. The results obtained in this study are considered worthy of further verification.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.